Sitryx Therapeutics (NASDAQ: SITX) Advances GLS1 Inhibitor for Asthma Treatment
Key Developments Sitryx Therapeutics (NASDAQ: SITX), a clinical-stage biopharmaceutical firm, has declared the selection of its leading glutaminase-1 (GLS1) inhibitor as a candidate for further clinical development targeting moderate to severe asthma. The company is now advancing this novel oral therapy into regulatory non-clinical studies with the goal of obtaining authorization for human clinical trials. This progress reflects Sitryx Therapeutics’ commitment to pioneering immune-modulating treatments designed to restore immune balance…
